Abstract:Blood and urine samples were collected weekly from an Asian elephant (Elephas maximus) for 10 months before conception, throughout pregnancy, and for 10 months after parturition. Additional daily samples were collected for 41 days before through 10 days after parturition to define endocrine events during the peripartum period. During gestation, serum progesterone concentrations increased gradually and, after -13 weeks, were higher ( P < 0.05) than those observed during the nonpregnant luteal phase. Concentrati… Show more
“…Serum progestagens were analyzed by using a solid-phase 125 I-progesterone radioimmunoassay (Coat-a-Countt, Siemens Diagnostic Products Corporation, Costa Mesa, California 92626, USA) validated for elephants. 7 Serum FSH and LH concentrations were quantified by using double antibody 125 I radioimmunoassays validated for elephants. 6 Hormone results were analyzed from samples collected approximately weekly from 4 January 2006 to 6 January 2010.…”
This report describes the successful use of a gonadotropin-releasing hormone (GnRH) vaccine to suppress ovarian steroidogenic activity and to treat hemorrhage and anemia associated with reproductive tract pathology in a 59-year-old Asian elephant (Elephas maximus). The Repro-BLOCt GnRH vaccine was administered subcutaneously as a series of 4 boosters of increasing dose from 3 to 30 mg of recombinant ovalbumin-GnRH fusion protein given at variable intervals after initial vaccination with 3 mg protein. Efficacy was confirmed over a year after initial vaccination based on complete ovarian cycle suppression determined by serum progestagen analyses. Estrous cycle suppression was associated with a significant increase in GnRH antibody binding and subsequent decrease in serum luteinizing hormone and follicle-stimulating hormone concentrations. Ultrasonographic examinations of the reproductive tract documented a reduction in uterine size and vascularity after immunization. The hematocrit level normalized soon after the initial intrauterine hemorrhage, and no recurrence of anemia has been detected. No substantive adverse effects were associated with GnRH vaccination. The results indicate that GnRH vaccination in elephants shows potential for contraception and management of uterine pathology in older elephants.
“…Serum progestagens were analyzed by using a solid-phase 125 I-progesterone radioimmunoassay (Coat-a-Countt, Siemens Diagnostic Products Corporation, Costa Mesa, California 92626, USA) validated for elephants. 7 Serum FSH and LH concentrations were quantified by using double antibody 125 I radioimmunoassays validated for elephants. 6 Hormone results were analyzed from samples collected approximately weekly from 4 January 2006 to 6 January 2010.…”
This report describes the successful use of a gonadotropin-releasing hormone (GnRH) vaccine to suppress ovarian steroidogenic activity and to treat hemorrhage and anemia associated with reproductive tract pathology in a 59-year-old Asian elephant (Elephas maximus). The Repro-BLOCt GnRH vaccine was administered subcutaneously as a series of 4 boosters of increasing dose from 3 to 30 mg of recombinant ovalbumin-GnRH fusion protein given at variable intervals after initial vaccination with 3 mg protein. Efficacy was confirmed over a year after initial vaccination based on complete ovarian cycle suppression determined by serum progestagen analyses. Estrous cycle suppression was associated with a significant increase in GnRH antibody binding and subsequent decrease in serum luteinizing hormone and follicle-stimulating hormone concentrations. Ultrasonographic examinations of the reproductive tract documented a reduction in uterine size and vascularity after immunization. The hematocrit level normalized soon after the initial intrauterine hemorrhage, and no recurrence of anemia has been detected. No substantive adverse effects were associated with GnRH vaccination. The results indicate that GnRH vaccination in elephants shows potential for contraception and management of uterine pathology in older elephants.
“…The major source of PRL is the anterior pituitary gland, and its major functions during mammalian gestation are development of the mammary glands and stimulation of milk production. PRL secretion is stimulated by several environmental factors including pregnancy, suckling stimulation and stress [2,[6][7][8][9][10][11][12].Reproductive endocrinology including secretion of PRL has been studied in elephants previously [13][14][15][16][17][18][19][20][21][22]. However, many mysteries, such as the source and the function of PRL during pregnancy, still remain.…”
Abstract. The objective of the present study was to define the secretion of prolactin (PRL) in pregnant African and Asian elephants. Levels of immunoreactive (ir-) PRL in serum and placental homogenates were measured by a heterologous radioimmunoassay (RIA) based on an ovine and human RIA system, and the localization of ir-PRL in the placenta was detected by immunohistochemistry using anti-human PRL. Circulating ir-PRL clearly showed a biphasic pattern during pregnancy in African and Asian elephants. Serum levels of ir-PRL started to increase from the 4 -6th month of gestation and reached the first peak level around the 11-14th month. A second peak of circulating ir-PRL levels was observed around the 18-20th month of gestation followed by an abrupt decline after parturition. In contrast, in a case of abortion of an African elephant, the second peak of ir-PRL was not observed, and the levels remained low for about four months until parturition. The weight of the fetus delivered at the 17th month of gestation was 23.5 kg, which was quite small compared with normal fetuses in previous reports. Ir-PRL was detected in placental homogenates, and immunolocalization was observed in trophoblasts in both the African and Asian elephants, indicating that the placenta is the source of ir-PRL during pregnancy in elephants. The present results clearly demonstrated that circulating ir-PRL shows a biphasic pattern during normal pregnancy and that the placenta appears to be an important source of circulating ir-PRL during pregnancy in both African and Asian elephants. Key words: Female elephant, Fetal growth, Placenta, Pregnancy, Prolactin (J. Reprod. Dev. 58: [105][106][107][108][109][110][111] 2012) G estation and parturition are dramatic events for a female animal. The secretion of prolactin (PRL) shows remarkable changes during gestation and at parturition in many species [1][2][3][4][5]. The major source of PRL is the anterior pituitary gland, and its major functions during mammalian gestation are development of the mammary glands and stimulation of milk production. PRL secretion is stimulated by several environmental factors including pregnancy, suckling stimulation and stress [2,[6][7][8][9][10][11][12].Reproductive endocrinology including secretion of PRL has been studied in elephants previously [13][14][15][16][17][18][19][20][21][22]. However, many mysteries, such as the source and the function of PRL during pregnancy, still remain. It is known that PRL is derived from the placenta in humans and rats [2,[23][24][25][26]. Placentation begins at the second to third month after ovulation in elephants [27]. The placenta ultimately forms a zonary shape, and its weight at term ranges from 8.3 to 22.2 kg in elephants [28].The objectives of the present study were to investigate the secretory pattern of immunoreactive (ir-) PRL in pregnant elephants. In addition, the immunoreactivity of ir-PRL was detected in the term placental tissues of both of African and Asian elephants by radioimmunoassay and immunohistochemistry.
Materi...
“…To assess prolactin immunoactivity, matched blood and urine samples were collected during mid to late gestation (12-18 months; Brown and Lehnhardt, 1995) from a single pregnant Asian and African elephant (n = 10 samples each) and compared to samples from nonpregnant females (n = 10 samples each species). In addition to longitudinal analyses, urine pools (n = 3 pools from at least six samples collected at $12, 15 and 18 months gestation) also were prepared for tests of parallelism (neat to 1:32) and mass recovery (0.31-40 ng mL À1 ).…”
Section: Animals and Sample Collectionmentioning
confidence: 99%
“…Serum samples were analyzed in duplicate for progestagen immunoactivity using a solid-phase 125 I progesterone radioimmunoassay (RIA) (Siemens Medical Diagnostic Solutions, Costa Mesa, CA) as previously described (Brown and Lehnhardt, 1995;Brown et al, 2004a,b). Elephant serum and urine samples were analyzed in duplicate for LH using a double-antibody RIA, validated for elephants, that relied on a monoclonal anti-bovine LH antiserum (518-B7; Coralie Munro, University of California, Davis), ovine 125 I-LH tracer and ovine LH standards (NIDDK-oLH-I-4; AFP8614B), and anti-mouse IgG second antibody (#M8645, Sigma Chemical Co., St. Louis, MO; 1:100) (Brown et al, 2004a,b).…”
Section: Hormone Analysesmentioning
confidence: 99%
“…Elephant serum and urine samples were analyzed in duplicate for LH using a double-antibody RIA, validated for elephants, that relied on a monoclonal anti-bovine LH antiserum (518-B7; Coralie Munro, University of California, Davis), ovine 125 I-LH tracer and ovine LH standards (NIDDK-oLH-I-4; AFP8614B), and anti-mouse IgG second antibody (#M8645, Sigma Chemical Co., St. Louis, MO; 1:100) (Brown et al, 2004a,b). Serum and urine samples were analyzed in duplicate for prolactin using a validated assay for elephants that relied on an anti-human prolactin antiserum (NIDDK-anti-hPRL-3), ovine 125 I prolactin label and standards (NIDDK-oPRL-I-2), and sheep anti-rabbit IgG second antibody (PKC-SARGG, Pool D; 1:300 in buffer with 5% polyethylene glycol; Uniformed Services University, Bethesda, MD) (Brown and Lehnhardt, 1995).…”
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.